Resource Logo
NLM AIDSLINE

Evolution of the skin lesions developed through HIV infection in children undergoing AZT treatment.




 

Int Conf AIDS. 1998;12:1015 (abstract no. 60080). Unique Identifier :

BACKGROUND: The report was drafted as a feedback evaluation during a period of 1 year within the day care ward for HIV/AIDS infected children at the "Colentina" Infectious Disease Hospital--Bucharest, Romania. The appraisal group consisted of 98 children, 48 of them without ARV treatment (antiretroviral), that is group 1 and another 50 being subject to ZDV monotherapy, that is group 2. The average age of these children was around 8 years old with limits between the ages of 2 and 13. As for the disease transmission way, it was exclusively non-vertical. The skin lesion assessment was first done on both groups before the cure with ARV and then periodically repeated every 3 month. The following skin lesions were observed during the study: infectious lesions:--bacterial fungal vital parasitic inflammatory lesions malignant neoplasias FEEDBACK: All types of lesions described above were presents in both groups; as far as the group treated with ARV, a drop was noticed in the occurrence of parasitic and fungal infections; the herpetic and zoster lesions had a slower development and a scarcer occurrence amongst the children treated with ARV; though several malignant neoplasias occurred amongst the children from both groups, these did not surface at the skin level. COMMENTS: Though the ARV monotherapy is no longer recommended nowadays, and we have stopped using it also, it is worth emphasizing the softened development of the HIV symptomatic infection at the children who received ARV treatment. Given the lack of immunity monitoring means, the skin lesions (fungal, vital) can stand as a token for the immunity drop.

MEETING ABSTRACTS Adolescence Child Child, Preschool Female Human HIV Infections/*DRUG THERAPY Male Reverse Transcriptase Inhibitors/*THERAPEUTIC USE Romania Skin Diseases, Infectious/*DRUG THERAPY Treatment Outcome Zidovudine/*THERAPEUTIC USE



 




Information in this article was accurate in December 30, 1998. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.